Ventilator associated pneumonitis (VAP).
Conditions
Interventions
Intervention 1: Intervention group: 2 cc/day vitamin D with the dose of 100000 units orally for five days from Zahravi drug company. Intervention 2: Control group: 2 cc/day olive oil as placebo for fi
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Pneumonia Severity Index (PSI) score above 51 The level of vitamin D below 20 ng/ml at the admission to the hospital Absence of hypercalcemia at the admission to the hospital (calcium concentration above 10.8 mg/dl) Stable hemodynamic status Not consuming hydrochlorothiazide, digoxin and magnesium containing antacids Absence of history of consuming vitamin D during the past four months with the dose above 1000 units Able to be be fed enterally at the 24 to 48 hours from the admission time Signing the consent form by the family of patients Absence of any of these disease: hyperparathyroidism, nephrolithiasis, sarcoidosis, chronic kidney disease, cirrhosis, metabolic diseases, acquired immune deficiency syndrome (AIDS), cardiovascular disease, diabetes mellitus, cancers and autoimmune diseases Not being pregnant Not involved in other research projects
Exclusion criteria
Exclusion criteria: Presence of other types of pneumonitis Dying earlier than 7 days of intervention Presence of any condition leading to enteral feeding disruption during the first 5 days of intervention If the supplementation is thought to be hazardous or being forbidden by the general practitioner
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Morbidity and organ failure calculated by the Sequential Organ Failure Assessment (SOFA) score, mortality risk assessed by the Acute Physiology and Chronic Health Enquiry (APACHE-II) score and change in the Pneumonia Severity Index (PSI) score. Timepoint: Completing the questionnaires and telephone contact about death after releasing from hospital in the 28 days after intervention. Method of measurement: SOFA, APACHE-II and PSI questionnaire and mortality numbers by telephone for released patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| SOFA, APACHE-II and mortality rate. Timepoint: On day 0, 7 and 14 of the intervention. Method of measurement: On day 0, 7 and 14 of the beginning of the intervention we will complete the SOFA & APACHE-II questionnaire and on day 28 we will ask the family of the patients for death after releasing from hospital. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Abolfazl Azariyan
Shiraz University of Medical Sciences
Outcome results
None listed